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embolization (SCBE)Abstract Large number of infective endocarditis (IE) patients remain clinically silent till hemor-
rhagic events occur with very poor outcome. The aim of this work was to study the impact of detec-
tion of this silent group by cerebral CT angiography (CTA) – which is not a standard practice – on
the treatment decisions and outcome in patients with left sided IE.
Patients and methods: From July 2007 to December 2012, 81 patients with left-sided IE (mean age
was 30.43 ± 8.8 years. 49 males) had brain CTA within 1 week of admission. All patients with
ICMA underwent four-vessel angiography. Treatment of intracranial mycotic aneurysms (ICMA)
was done either by endovascular or surgery.
Results: Brain CTA revealed 51 patients with cerebral embolization. 26 patients had ICMA, 13
went for endovascular treatment 6 of them were clinically silent. 2 went for open surgery and 11
spontaneously thrombosed on treatment. The ﬁndings in brain CTA prompted changes in treat-
ment decisions in 21 patients (25.6%). The mortality in ICMA patients was 19.2% which is signif-
icantly lower than most of the published literature.
Conclusion: Routine assessment of patients with left sided IE by cerebral CTA can change the
treatment plans leading to signiﬁcant reduction in mortality rate and improved outcome.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
Despite the advances in diagnostic and therapeutic modalities,
infective endocarditis (IE) remains a challenging disease withhigh rates of mortality and morbidity (1). Infective endocardi-
tis (IE) is a condition resulting from microbial infection of the
endothelial lining of intracardiac structures and is highly fatal
if untreated. Infection most commonly resides on one or more
heart valve leaﬂets, but may involve mural endocardium, chor-
dal structures, myocardium and pericardium (2).
The disease may also occur within septal defects or on con-
genitally malformed structures. Infections of the great vessels,
arteriovenous shunts and of arterioarterial shunts (like patented.
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the aorta (2).
Clinically manifest neurological complications occur in 20–
40% of IE patients and are mostly due to septic brain emboli-
zation and formation of intracranial mycotic aneurysm
(ICMA) (2). Neurological complications in (IE) are strong pre-
dictors of mortality which is between 60% and 83% with rup-
tured (ICMA) (3–5). Most of the ICMA remain silent and
rupture suddenly with catastrophic consequences (6,7).
Intracranial mycotic aneurysms (ICMA) are rare compared
with berry aneurysms. They develop as a consequence of vessel
wall necrosis due to showering of bacterial emboli into the cir-
culation, their evolution is unpredictable even after the com-
mencement of antibiotic therapy, they can regress, develop
de novo, or rupture (5). Occlusion of the aneurysm has been
recommended, either by surgery (8–10) or more recently, with
endovascular means (11–14).
Sub-clinical infarcts, cerebral hemorrhage or rupture ICMA
can complicate the course of treatment and alter treatment
decisions, particularly in patients who require cardiac surgery
and valve replacement. Despite the high incidence and the
grave prognosis, routine screening for neurological complica-
tions is not a standard practice in (IE). The aim of this work
was to detect the impact of early screening of these complica-
tions by cerebral CTA on the treatment decision and outcome
in patients with (IE) affecting the left side of the heart.
2. Patients and methods
From July 2007 to December 2012 we prospectively recruited
81 consecutive patients with left-sided IE conﬁrmed by
Trans-thoracic or trans-esophageal echography and blood/
serology cultures. The mean age was 30.43 ± 8.8 years.
Forty-nine were males (60.5%). All patients performed cere-
bral CT angiography (CTA) within 7 days of admission
regardless of the presence of manifest neurological complaint,
for which informed consent was obtained. Patients were exam-
ined on a 64-MDCT scanner Toshiba Aquilion (Toshiba Med-
ical Systems Europe B.V. Zoetermeer, The Netherlands). All
examinations were reviewed and discussed by two neuro-radi-
ologists who assessed the presence, number, location and size
of ICMA as well as the associated ﬁndings e.g. strokes, vaso-
spasm and occlusions.
Patients were classiﬁed as having clinical evidence of brain
embolization (symptomatic) if they had either new onset of a
persistent focal neurological deﬁcit or a transient ischemic
attack (TIA) deﬁned as brief episodes of neurological dysfunc-
tion resulting from focal cerebral ischemia not associated with
permanent cerebral infarction (15).
We diagnosed aneurysms as mycotic in the setting of deﬁ-
nite IE and had one of the following criteria:
 The presence of another intra- or extra-cranial mycotic
aneurysm.
 Rupture of the aneurysm.
 Arterial occlusion or stenosis adjacent to the aneurysm.
 Cerebral infarction due to arterial occlusion at the level of
the aneurysm (16).
Patients with ICMA by CTA performed digital subtraction
angiogram and went for treatment if they had one of the
following: ICMA diameter P5 mm.
 Evidence of leak around the ICMA.
 Location of the ICMA in the same territory of a symptom-
atic cerebral infarction.
 Increase in ICMA size on subsequent follow up studies.
Patients with ICMA <5 mm were scheduled for follow up
angiography after two weeks of proper antimicrobial therapy.
If the ICMA regressed or remained stable, then patients were
managed conservatively. When cardiac surgery was performed
in patients with ICMA, it had to be either valve repair or
replacement by biological valve. We decided to hold oral anti-
coagulation in patients with ICMA and to postpone non-emer-
gent cardiac surgery for 2 weeks in these patients even if
asymptomatic. Cardiac surgery was also postponed for
2 weeks in patients with cerebral hemorrhage or large cerebral
infarcts even if asymptomatic. We excluded patients who
refused to sign the informed consent and patients who refused
angiography. The local ethical committee approved the study
protocol.
Thirteen patients in this study went for endovascular treat-
ment. Technical details were discussed with the patient or rel-
atives and an informed consent was obtained for the
procedures. All endovascular treatment procedures were per-
formed under general anesthesia. A guiding catheter 6-F was
introduced till the upper cervical level with continuous ﬂushing
with normal saline. Intravenous heparin shots to obtain an
activated partial thromboplastin time two to three times base-
line were performed.
Distally located aneurysms (n= 10) were treated with
endovascular parent artery occlusion (PAO) where selective
occlusion of the aneurysmal sac with coils cannot be achieved.
Usually adequate collateral circulation in young age group
treated by PAO prevents infarction in the territory of the
occluded vessel. If infarction occurs, the clinical consequences
are going to be limited or clinically silent (17,18). Coiling was
done for proximal aneurysms (n= 3).
For distal aneurysms a ﬂow-guided microcatheter (Magic,
Balt, France) or an over-the-wire microcatheter (Excel 10, Tar-
get Therapeutics)) was used. The microcatheter was positioned
as close as possible to the aneurysm to occlude the parent
artery and the aneurysmal sac using cyanoacrylate (Histoacryl;
B Braun, Melsungen, Germany) mixed with iodized oil (Lipi-
odol Ultra Fluide; Laboratoire Guerbet, Paris, France) in
ratios varying from 1:1 to 1:3. In proximal aneurysms selective
treatment by coiling was performed with a technique similar to
that used in the treatment of berry aneurysms using Guglielmi
detachable coils (Target Therapeutics).
3. Results
The cerebral CTA ﬁndings, clinical features, and complica-
tions in our study group are demonstrated in Table 1 and Dia-
gram 1.
Twenty-six patients had ICMA by CTA, 15 of them were
clinically silent. Associated 3 extra-cranial mycotic aneurysms
were found in two patients; one involving the right ICA at its
cervical segment with consequent occlusion of the vessel in one
patient while the other patient had 2 in the left renal and supe-
rior mesenteric arteries The ﬁrst was successfully treated with
antibiotics, the second was managed by endovascular proce-
dure and surgical repair.
Table 1 Clinical feature, CT ﬁndings and complications in 81
patients having left sided IE.
Variable N (% to 81)
Underlying pathology
Rheumatic 30 (37%)
Prosthetic valve 21 (26%)
Normal heart 19 (23.5%)
Congenital heart disease 7 (8.6)
Degenerative valve disease 4 (5%)
Mitral valve 46 (56.8%)
Aortic valve 19 (23.5%)
Both valves 13 (16%)
Associated health problems 25 (30.9)






Culture/serology – negative 15 (18.5%)
Cerebral CTA ﬁndings
Normal 30 (37%)
Cerebral embolization 51 (63%)
Manifest embolization 34 (42%)
Silent embolization 17 (21%)
Silent infarction 1 (1.2%)
Manifest infarction 17 (21%)
Silent cerebral hemorrhage 2 (2.5%)
Manifest cerebral hemorrhage 20 (24.7%)
ICMA 26 (32%)
Major complications 63 (77.8%)
Sepsis requiring ventilation or vasopressor 23 (28.4)
Systemic embolization other than CNS 49 (60.5%)
Heart failure 40 (49.4%)
Death 15 (18.5%)


















Diagram 1 Cerebral CTA ﬁndings and prevalence of ICMA in
both symptomatic and clinically silent groups.
Role of cerebral CTA screening in patients with endocarditis 119Thirteen patients with ICMA were successfully treated by
endovascular treatment (EVT). All procedures were performed
under general anesthesia, 10 distal ICMA were treated withPAO and 3 proximal ICMAwere treated by coiling. There were
no clinical changes after treatment in 11 patients. Transient
complications occurred in two patients with distal ICMA in
the form of a transient hemiparesis that resolved spontaneously
within 48 h. Eight patients underwent cardiac surgery within
1 week of EVT without cerebral complications (Figs. 1–3).
The ﬁndings of cerebral CTA changed the treatment plans
in 21 patients (25.6%). Eleven of them were neurologically
asymptomatic and in 11 patients more than one change in
the treatment plan was taken. These changes were as follows:
 Fifteen patients were referred for surgical or endovascular
treatment of the ICMA based on the indications previously
mentioned; 8 of them (53.3%) were asymptomatic. Thirteen
patients were referred for endovascular treatment, 6 of them
were neurologically silent. Two patients had postprocedure
transient hemiparesis that resolved after 48 h. Two patients
were referred for surgical treatment of ICMA that were not
amenable to endovascular treatment; both were neurologi-
cally silent and had no procedure-related complications.
 Anticoagulation was stopped in 3 patients with prosthetic
valve IE due to the presence of ICMA, 2 of them were
silent.
 In 17 patients, we had to change the type of cardiac surgery
from scheduled mechanical valve replacement to repair or
biological valve replacement as they had ICMA or asymp-
tomatic hemorrhage. Eight of them had no neurological
manifestation.
Among the 26 patients with ICMA, 21 patients (81%) had
their management strategy modiﬁed. This ratio was 73% in
those with silent ICMA (11 out of 15 cases) where the detec-
tion of their asymptomatic ICMA led to the modiﬁcation of
their treatment plans. Mortality was 19.2% in patients with
ICMA (5 out of 26) and was 66.7% in patients with ruptured
ICMA (2 out of 3). The overall mortality incidence in this
study was 15 patients (18.5%) and 12 of them (80%) had neu-
rologic complications.4. Discussion
In spite of the great advances in diagnostic and therapeutic
modalities, infective endocarditis IE remains a challenging,
non-tamed, wild disease with one of the highest rates of mor-
bidity and mortality ever. In some studies, infective endocardi-
tis mortality is classiﬁed as the fourth leading fatal infectious
disease (19).
In most of the published reports and studies, there was
a general agreement that every case outcome was signiﬁ-
cantly affected by the causative organism, the valve
affected and the complications occurred to such a case
(19). It is known that clinically manifested neurologic com-
plications that are mostly due to acute brain embolization
are evident in about 20–40% of endocarditis patients (20–
23). Endocarditis neurologic sequelae are associated with
poor outcomes (19).
The new surprising fact that was recently taken into consid-
eration is the presence of large proportion of IE patients with
brain embolization remained neurologically silent i.e. sub-clin-
ical brain embolization (SCBE). This fact was proved either by
autopsy data or by routine imaging. Computed tomography
Fig. 1 (A) CTA in a clinically free patient showing Lt middle cerebral two distal mycotic aneurysms with occlusion of the Rt internal
carotid artery in the neck. (B) Digital subtraction angiogram showing the two aneurysms- arrowed. (C) Microcatheter at the neck of the
aneurysm. (D) Occlusion of both by Cyanoacrylate/Lipiodol mixture. (E) Digital subtraction angiogram after treatment. (F) MRI FLAIR
post-treatment showing small clinically silent ischemic focus (arrowed).
120 A.Z. Ahmed et al.was ﬁrst tried in studies made by Thuny et al. and Di Salvo
et al. (7,24,25).
Previous studies were inconsistent regarding the incidence
of brain embolization in IE and did not use vascular imaging
systemically. Thuny et al. (7) utilized cerebral and thoraco-
abdominal CT that revealed silent emboli in only 8% of
patients. Cooper et al. (6) performed brain MRI in 40 patients
with IE and found acute brain embolization in 80% of
patients. Iung et al. (26) performed routine cerebral MRI
and detected ischemic lesions in 53.3% of their 64 patients.
Iung et al. also performed routine abdominal and cerebral
MRI in 58 patients with suspected IE within 7 days following
admission. They modiﬁed therapeutic plans in 19% of their
patients, based on cerebral MRI, including modiﬁcation of
surgical plans in 10% of patients (27).
MRI was found to be more sensitive than CT in evaluation
of SCBE events. A fact that was made obviously clear in thestudy made in Washington Hospital Center which revealed
that SCBE events were as common as 48% of the studied pop-
ulation. It also stated that 95% of patients with Staph. endo-
carditis had MRI evidence of SCBE, despite only about their
half had clinical manifestations (28).
The question about the impact of the SCBE posed on IE
course and whether they can independently affect the outcome
was addressed by same study from Washington Hospital
Center showing that IE related mortality was equal between
patients with clinical strokes and SCBE and it is much higher
than in patients without brain embolization 56% versus 12%
(28).
In the Finnish study that included 218 deﬁnite IE episodes
found that neurologic complications are quite common in
infective endocarditis and that it carries poor prognosis than
neurologically uncomplicated cases. From the 218 cases stud-
ied, 84 (39%) had a neurologic complication and 58% of these
Fig. 2 (A) CT showing intracerebral and intraventricular bleeding secondary to rupture mycotic aneurysm. (B and C) Showing mycotic
aneurysm along the left MCA branches. (D) Selective closure of the aneurysm and parent artery by Cyanoacrylate/Lipiodol mixture. (E
and F) Final control showing closure of the aneurysm and MCA branch.
Role of cerebral CTA screening in patients with endocarditis 12184 patients died. In contrast, the mortality rate was only 20%
among those endocarditis patients without neurologic compli-
cations (29).
Most of the SCBE will cause ischemic insults or micro-hem-
orrhages that mostly remain clinically silent, but those causing
ICMA are the biggest concern. Duval who examined 130 left
sided infective endocarditis patients with MRI/MRA andfound that 16 patients (12%) had acute neurologic symptoms.
Cerebral lesions were detected by MRI in 106 patients (82%),
including ischemic lesions in 68 (64.1%) micro-hemorrhages in
74 (69.8%), and silent aneurysms in 10 (9.4%) (30).
In the French study by Thuny et al., 496 consecutive
patients with deﬁnite IE were enrolled. Cerebral (CT) scan
with contrast was systematically performed on admission in
Fig. 3 (A) Ruptured mycotic aneurysm at the right MCA bifurcation with occlusion of the anterior temporal division. (B) Closure of the
aneurysm by coiling. (C) Control angiogram showing total closure of the aneurysm with patent remaining MCA branches.
122 A.Z. Ahmed et al.453 patients and was repeated if clinically indicated. A silent
cerebral embolism was present in 17/453 patients (3.8%) (31).
In this study, we included 81 patients with left sided infec-
tive endocarditis. Neurologic complications were found in 51
patients (63%). All patients had cerebro-vascular imaging
using CT angiography. The incidence of neurologic complica-
tions in this study is higher than in the literature, it ranges
between 20% and 40% in most of the published reports
(17,21–23). This can be due to the detection of silent cases
by CTA screening done and the fact that we work in a tertiary
care center and receive complicated patients from other centers
late in their course.
Considering ICMA from the other than CNS complica-
tions, the results derived from this study were comparable with
the results were derived from Washington Hospital Center
study (28), Duval et al. study (30), and Thuny et al. study
(31). Clinically manifesting ICMA incidence was 13.6% (11
among the 81 studied patients). The clinical presentation in
these cases was ischemic stroke and was complicated in 7 of
them by hemorrhagic transformation. By routine screening this
incidence jumped to be 32.1% (15 more silent ICMA cases).
This means that silent ICMAs comprised 57.7% (15 out of
26) from all ICMA cases, which is relatively a large ratio.
Regarding IE related mortality, the overall mortality inci-
dence in this study was signiﬁcantly low (18.5%) compared
to the known IE related mortality which ranges from 26 to
more than 31% (32,33). This study conﬁrms the fact that
CNS complications carry higher mortality rates than neurolog-
ically free patients. Among the mortality cases that occurred in
this study 80% (12 out of 15) had neurologic complications.
Re-reading this data from the other view made mortality inci-
dence 14.8% vs. 3.7% in patients with vs. without CNS com-
plications respectively.
In this study routine cerebrovascular imaging had caused a
remarkable decline in endocarditis related mortality in patients
with neurologic complications 14.8% (12 of 81 patients) com-
pared to the universal reports, where the mortality in equiva-
lent population in the Finnish study (58%) (30), the
Washington university hospital study (62%) (28) or in Sonne-
ville, Mirabel, et al. study (62%) (34). Despite that we had a
higher incidence of neurologic involvement in our patients, this
decline in mortality rates is a strong proof that early detection
and the sound optimization of management plans in patients
found to have any acute brain embolization whether manifest-
ing or silent can dramatically affect mortality rates.ICMA cases in the past were only discovered when symp-
tomatic and remain silent until massive complications occur,
in most of the cases massive intracranial hemorrhage. The lit-
erature reports mortality rates around 60% and higher in
endocarditis patients with ICMAs. This rate jumps abruptly
to become 80–90% if ICMA ruptures (35,36). However by
routine cerebral CTA, and by the strategy we adopted target-
ing early detection of silent mycotic aneurysms, and appropri-
ate sound management of aneurysms needing intervention
either by endovascular repair or by surgical clipping, mortality
was reduced to 15.3% (4 out of 26). This ratio (15.3%) counts
for total ICMA cases mortality which is around the fourth of
the rates in published reports (60%) (5). The mortality rate
among patients with ruptured ICMA was 66.7% (2 out of 3)
which is comparable with the published data 80–90%.
The cost effectiveness of routine screening appeared to be
very favorable by early detection and appropriate treatment
plan and modiﬁcation of the affected cases. Comparing the
cost of routine cerebral CTA in patients with deﬁnite left sided
IE to the lives saved (reducing mortality from 60% to15.3%)
added to the costs that might have been spent for management
of patients if they develop unexpected massive intracranial
hemorrhages from silent ICMA ruptures (such as having neu-
rosurgical intervention or special care to comatosed patients),
all these come in favor of routine CTA imaging to all patients.
It is worth mentioning that none of the patients who went for
neurovascular procedure had related permanent morbidity or
mortality. To our knowledge this is the ﬁrst study to use rou-
tine cerebral CTA to assess brain embolization in patients with
left-sided IE and its impact on the treatment plans.
5. Conclusion
Routine assessment of patients with aortic/mitral infective
endocarditis (IE) by cerebral CTA changed the treatment plans
in a large group of patients with signiﬁcant reduction in the
mortality rate. This screening method is safe and may poten-
tially improve the outcome of IE patients. We recommend
more studies to compare the implementation of routine screen-
ing by cerebral CTA versus the standard care in IE patients.
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